Comparative Pharmacology
Head-to-head clinical analysis: ONCOVIN versus VINCRISTINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ONCOVIN versus VINCRISTINE SULFATE.
ONCOVIN vs VINCRISTINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vincristine is a vinca alkaloid that binds to tubulin, inhibiting microtubule formation and disrupting mitotic spindle assembly, leading to metaphase arrest and cell death.
Vincristine is a vinca alkaloid that binds to tubulin, inhibiting microtubule assembly and causing metaphase arrest in dividing cells. It disrupts mitotic spindle formation, leading to cell cycle arrest at M-phase and apoptosis in rapidly proliferating cells.
1.4 mg/m2 IV weekly, maximum single dose 2 mg
1.4 mg/m2 IV push once weekly, maximum single dose 2 mg.
None Documented
None Documented
Terminal elimination half-life: approximately 19-155 hours (mean ~85 hours) in adults. In elderly and hepatic impairment, half-life is prolonged. Highly variable due to extensive tissue binding and prolonged terminal phase.
Terminal elimination half-life: 19-35 hours (mean ~24 hours) in adults; prolonged to up to 85 hours in hepatic impairment or elderly.
Primarily hepatobiliary (fecal) excretion: ~80% as unchanged drug and metabolites via bile into feces. Renal excretion: <10% unchanged in urine. Extensive metabolism in liver via CYP3A4.
Primarily biliary/fecal: ~70-80% excreted unchanged in bile and feces; renal: ~10-20% as unchanged drug and metabolites.
Category C
Category D/X
Vinca Alkaloid
Vinca Alkaloid